SG11201805927YA - Spiroheptane salicylamides and related compounds as inhibitors of rock - Google Patents

Spiroheptane salicylamides and related compounds as inhibitors of rock

Info

Publication number
SG11201805927YA
SG11201805927YA SG11201805927YA SG11201805927YA SG11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA
Authority
SG
Singapore
Prior art keywords
pennington
new jersey
myers squibb
co7d
bristol
Prior art date
Application number
SG11201805927YA
Inventor
Ii Leon M Smith
Vladimir Ladziata
Indawati Delucca
Donald Pinto
Michael J Orwat
Andrew K Dilger
Kumar Balashanmuga Pabbisetty
Wu Yang
Scott A Shaw
Peter W Glunz
Manoranjan Panda
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201805927YA publication Critical patent/SG11201805927YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, - Organization 11111111011110111010101111101011111011101110111101111011001101111101111011111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... .... WO 2017/123860 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: New Jersey 08534 (US). LADZIATA, Vladimir; c/o Bris- CO7D 401/14 (2006.01) CO7D 401/12 (2006.01) tol-Myers Squibb Company, 311 Pennington-Rocky Hill A61K 31/437 (2006.01) CO7D 413/12 (2006.01) Road, Pennington, New Jersey 08534 (US). DELUCCA, A61K 31/4427 (2006.01) CO7D 471/04 (2006.01) Indawati; c/o Bristol-Myers Squibb Company, 311 Pen- CO7D 231/12 (2006.01) CO7D 471/12 (2006.01) nington-Rocky Hill Road, Pennington, New Jersey 08534 CO7D 231/18 (2006.01) CO7D 513/04 (2006.01) (US). PINTO, Donald, J., P.; c/o Bristol-Myers Squibb CO7D 231/54 (2006.01) CO7D 213/64 (2006.01) Company, 311 Pennington-Rocky Hill Road, Pennington, (21) New Jersey 08534 (US). ORWAT, Michael J.; c/o Bris- International Application Number: PCT/US2017/013323 tol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). DILGER, An- (22) International Filing Date: drew K.; c/o Bristol-Myers Squibb Company, 311 Pen- 13 January 2017 (13.01.2017) nington-Rocky Hill Road, Pennington, New Jersey 08534 (US). PABBISETTY, Kumar Balashanmuga; c/o Bris- tol-Myers Squibb Company, 311 Pennington-Rocky Hill (26) Publication Language: English Road, Pennington, New Jersey 08534 (US). YANG, Wu; c/o Bristol-Myers Squibb Company, 311 Penning- (30) Priority Data: ton -Rocky Hill Road, Pennington, New Jersey 08534 (US). 62/278,122 13 January 2016 (13.01.2016) US SHAW, Scott A.; c/o Bristol-Myers Squibb Company, 311 (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY Pennington-Rocky Hill Road, Pennington, New Jersey [US/US]; Route 206 and Province Line Road, Princeton, 08534 (US). GLUNZ, Peter W.; c/o Bristol-Myers Squibb New Jersey 08543 (US). Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). PANDA, Manoranjan; c/o SYN- = (72) Inventors: SMITH II, Leon M.; c/o Bristol-Myers Squibb GENE INTERNATIONAL LIMITED, Biocon Special Company, 311 Pennington-Rocky Hill Road, Pennington, Economic Zone, Biocon Park, Plot No. 2 & 3, Bommas- [Continued on next page] (54) Title: SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK (57) : The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutic- () ally-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhib- R 6 , A itors. This invention also relates to pharmaceutical composi- N R1 tions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, R2 autoimmune, fibrotic, and/or inflammatory disorders using the same. R 13 --.....„ _ R I 3 ---- R 12 o 12 ix ......__ (I) R\" (R 3 0_4 1-1 NH2 © GC en ei ,-1 IN ,-1 © ei O WO 2017/123860 Al MIDEDIMOMOIDEIR010130H01110MEHMEMOVOIMIE andra Industrial Area IV Phase, Jigani Line Road Born- (84) Designated States (unless otherwise indicated, for every (74) masandra Bangalore, Karnataka 560 099 (IN). Agents: LIU, Hong et al.; Bristol-Myers Squibb Corn- pany, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). kind of regional protection available): ARIPO (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, TZ, UG, ZM ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, ur , TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, GH, SZ, DE, LT, (81) Designated States (unless otherwise indicated, for every LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, kind of national protection available): AE, AG, AL, AM, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, GN, GQ, GW, KM, ML, MR, NE, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, Declarations under Rule 4.17: SN, TD, TG). SE, GA, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, — of inventorship (Rule 4.17(iv)) KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, Published: LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, — with international search report (Art. 21(3)) QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
SG11201805927YA 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock SG11201805927YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278122P 2016-01-13 2016-01-13
PCT/US2017/013323 WO2017123860A1 (en) 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock

Publications (1)

Publication Number Publication Date
SG11201805927YA true SG11201805927YA (en) 2018-08-30

Family

ID=57907009

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805927YA SG11201805927YA (en) 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock

Country Status (28)

Country Link
US (2) US10611776B2 (en)
EP (2) EP3954681A1 (en)
JP (2) JP6976953B2 (en)
KR (1) KR20180097749A (en)
CN (1) CN108699038B (en)
AR (1) AR107354A1 (en)
AU (2) AU2017206820B2 (en)
BR (1) BR112018013780B1 (en)
CA (1) CA3010900A1 (en)
CL (1) CL2018001899A1 (en)
CO (1) CO2018008173A2 (en)
CY (1) CY1124858T1 (en)
EA (1) EA036172B1 (en)
ES (1) ES2898698T3 (en)
HR (1) HRP20211888T1 (en)
HU (1) HUE057455T2 (en)
IL (1) IL260448B (en)
LT (1) LT3402790T (en)
MA (2) MA43862A (en)
MX (2) MX2018008219A (en)
PL (1) PL3402790T3 (en)
PT (1) PT3402790T (en)
RS (1) RS62690B1 (en)
SG (1) SG11201805927YA (en)
SI (1) SI3402790T1 (en)
TW (1) TWI730032B (en)
UY (1) UY37073A (en)
WO (1) WO2017123860A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112236A1 (en) 2015-01-09 2016-07-14 Bristol-Myers Squibb Company Cyclic ureas as inhibitors of rock
WO2016144936A1 (en) 2015-03-09 2016-09-15 Bristol-Myers Squibb Company Lactams as inhibitors of rock
UY37073A (en) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware SPIROHEPTAN SALICILAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS, AND THE COMPOSITIONS CONTAINING THEM
TWI635082B (en) 2016-01-13 2018-09-11 歌林達有限公司 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HUE049813T2 (en) 2016-01-13 2020-10-28 Gruenenthal Gmbh 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
RS60855B1 (en) 2016-01-13 2020-10-30 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CA3011180A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HUE061989T2 (en) 2016-03-16 2023-09-28 Kura Oncology Inc Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
WO2017205709A1 (en) 2016-05-27 2017-11-30 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of rock
WO2018009625A1 (en) 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Spirolactams as inhibitors of rock
CN110049977B (en) 2016-07-07 2022-01-18 百时美施贵宝公司 Lactam, cyclic urea and carbamate and triazolone derivatives as potent and selective ROCK inhibitors
KR102449652B1 (en) 2016-07-07 2022-09-29 브리스톨-마이어스 스큅 컴퍼니 Spiro-fused cyclic urea as inhibitor of ROCK
CN110023291B (en) 2016-11-30 2023-07-18 百时美施贵宝公司 Tricyclic RHO kinase inhibitors
WO2019014300A1 (en) 2017-07-12 2019-01-17 Bristol-Myers Squibb Company Phenylacetamides as inhibitors of rock
CN110914257B (en) * 2017-07-12 2023-05-26 百时美施贵宝公司 Spiroheptylhydantoins as ROCK inhibitors
JP7234201B2 (en) * 2017-07-12 2023-03-07 ブリストル－マイヤーズ スクイブ カンパニー Inhibitors of 5-membered aminoheterocycles and 5,6- or 6,6-membered bicyclic aminoheterocycles of ROCK for the treatment of heart failure
TW201908293A (en) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 5 members of ROCK inhibitor and bicyclic heterocyclic guanamine
EP3684361A4 (en) * 2017-09-20 2021-09-08 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
KR20200083543A (en) 2017-11-03 2020-07-08 브리스톨-마이어스 스큅 컴퍼니 Diazaspiro ROCK inhibitor
WO2024013736A1 (en) * 2022-07-12 2024-01-18 Adama Makhteshim Ltd. Process for preparing substituted benzamides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227480B2 (en) * 2006-06-08 2012-07-24 Ube Industries, Ltd. Indazole derivative having spiro ring structure in side chain
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
RU2457203C2 (en) * 2006-12-27 2012-07-27 Санофи-Авентис Cycloalkylamine-substituted isoquinolone derivatives
CL2007003874A1 (en) 2007-01-03 2008-05-16 Boehringer Ingelheim Int COMPOUNDS DERIVED FROM BENZAMIDA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CARDIOVASCULAR DISEASES, HYPERTENSION, ATEROSCLEROSIS, RESTENOSIS, ICTUS, HEART FAILURE, ISCHEMICAL INJURY, HYPERTENSION
NZ586335A (en) * 2007-12-26 2011-08-26 Sanofi Aventis Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
CN105073741B (en) 2013-01-18 2017-08-08 百时美施贵宝公司 It is used as the phthalazone and isoquinolines of ROCK inhibitor
TW201444798A (en) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
JP6522602B2 (en) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic pyrido-carboxamide derivatives as ROCK inhibitors
TW201506024A (en) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 Tricyclic carboxamide derivatives as potent ROCK inhibitors
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
WO2016112236A1 (en) 2015-01-09 2016-07-14 Bristol-Myers Squibb Company Cyclic ureas as inhibitors of rock
WO2016144936A1 (en) 2015-03-09 2016-09-15 Bristol-Myers Squibb Company Lactams as inhibitors of rock
UY37073A (en) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware SPIROHEPTAN SALICILAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS, AND THE COMPOSITIONS CONTAINING THEM
WO2017205709A1 (en) 2016-05-27 2017-11-30 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of rock
WO2018009625A1 (en) 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Spirolactams as inhibitors of rock
KR102449652B1 (en) 2016-07-07 2022-09-29 브리스톨-마이어스 스큅 컴퍼니 Spiro-fused cyclic urea as inhibitor of ROCK
CN110049977B (en) 2016-07-07 2022-01-18 百时美施贵宝公司 Lactam, cyclic urea and carbamate and triazolone derivatives as potent and selective ROCK inhibitors
CN110023291B (en) 2016-11-30 2023-07-18 百时美施贵宝公司 Tricyclic RHO kinase inhibitors

Also Published As

Publication number Publication date
RS62690B1 (en) 2021-12-31
MX2021005311A (en) 2021-06-23
MA43862A (en) 2021-06-02
JP7268116B2 (en) 2023-05-02
CO2018008173A2 (en) 2018-08-21
US10611776B2 (en) 2020-04-07
JP6976953B2 (en) 2021-12-08
EP3954681A1 (en) 2022-02-16
AU2017206820B2 (en) 2021-06-17
BR112018013780A2 (en) 2018-12-11
US20200131200A1 (en) 2020-04-30
JP2022024019A (en) 2022-02-08
US20190016735A1 (en) 2019-01-17
EA201891557A1 (en) 2019-01-31
TWI730032B (en) 2021-06-11
PT3402790T (en) 2021-11-22
UY37073A (en) 2017-07-31
EA036172B1 (en) 2020-10-09
CN108699038A (en) 2018-10-23
SI3402790T1 (en) 2022-01-31
AU2017206820A1 (en) 2018-08-23
PL3402790T3 (en) 2022-01-24
TW201726619A (en) 2017-08-01
LT3402790T (en) 2021-12-10
HUE057455T2 (en) 2022-05-28
JP2019509978A (en) 2019-04-11
BR112018013780B1 (en) 2023-12-19
CL2018001899A1 (en) 2018-11-09
MX2018008219A (en) 2018-09-07
WO2017123860A1 (en) 2017-07-20
AR107354A1 (en) 2018-04-18
IL260448B (en) 2020-09-30
AU2021221872A1 (en) 2021-09-23
ES2898698T3 (en) 2022-03-08
US10829501B2 (en) 2020-11-10
HRP20211888T1 (en) 2022-03-04
MA55633A (en) 2022-02-16
CA3010900A1 (en) 2017-07-20
CY1124858T1 (en) 2022-11-25
EP3402790A1 (en) 2018-11-21
KR20180097749A (en) 2018-08-31
CN108699038B (en) 2021-04-16
EP3402790B1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
SG11201805927YA (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201804934PA (en) Novel Compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201807980QA (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201408094YA (en) Neprilysin inhibitors
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201408678WA (en) Catalysts and methods for polyester production
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201407372UA (en) Nampt inhibitors
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF